Drug – bio-affecting and body treating compositions – Anti-perspirants or perspiration deodorants
Reexamination Certificate
2002-01-31
2003-01-21
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Anti-perspirants or perspiration deodorants
C424S066000, C424S068000, C424S400000, C424S401000, C514S288000, C514S452000, C514S460000
Reexamination Certificate
active
06509010
ABSTRACT:
FIELD OF INVENTION
This invention relates to cosmetic methods and products concerned with decreasing the acidity of sweat secreted from human eccrine glands, decreasing body malodour, and decreasing perspiration.
BACKGROUND OF INVENTION
Cosmetic deodorant compositions are known. Typical deodorant compositions comprise one or more agents that mask or inhibit the formation of unpleasant body odours; perfumes and/or antimicrobial agents are widely used for this purpose. Some deodorant compositions also reduce perspiration and are termed deodorant antiperspirant compositions, or antiperspirant compositions. Typical antiperspirant compositions comprise a metal antiperspirant salt, such as an astringent aluminium or aluminium/zirconium salt, in combination with a cosmetically suitable vehicle. Such cosmetic deodorant and antiperspirant products are available in a variety of product forms, for example as sticks, roll-on lotions, aerosols and pump spray formulations.
We have discovered a method of gaining a range of benefits, including improved deodorancy and antiperspirancy, by reducing the acidity of sweat secreted by human eccrine glands by topical application of a vacuolar (H+)-ATPase (or V-ATPase) inhibitor. Decreased acidity may result in any of the following benefits: increased desquamation and hence smoother skin (see M. M. Brysk et al,
Experimental Cell Research
, 214(1), 22-26, Sep. 1994); reduced volatility of odiferous short chain fatty acids on the skin surface and hence decreased body malodour; reduced acid-induced damage of cosmetic ingredients applied to the skin, in particular perfumes; and improved performance of antiperspirant compositions comprising an antiperspirant salt.
A method of elevating the pH of human sweat has previously been reported in WO 00/15185 (Beck et al). In this publication, the agent used to increase the pH was a bicarbonate reabsorption inhibitor. The present invention, in contrast, uses a V-ATPase inhibitor. V-ATPase inhibitors are disclosed in numerous publications, including WO 95/20043 (Stein and Tonkinson) and WO 00/51589 (Boyd); however, none of these publications disclose the methods or compositions of the present invention.
The present invention takes advantage of the recent discovery of vacuolar-type H+-ATPases (V-ATPases) in the luminal membrane of eccrine sweat ducts (Bovell D. L., et al,
The Histochemical Journal
, 32, 2000, 409-413).
SUMMARY OF INVENTION
We have found a new method for reducing the acidity of human sweat. The method involves the topical application of a vacuolar (H+)-ATPase (or V-ATPase) inhibitor. Such materials inhibit proton pumps in the luminal membrane of the sweat gland and thereby reduce the sweat gland's ability to acidify the sweat. Significantly, Example 1 of the present patent suggests that not all eccrine sweat ducts have active V-ATPases in the luminal membrane; hence, the present invention discloses a ‘selective’ method for increasing the pH of sweat secreted from eccrine sweat ducts. Unlike the prior art method involving bicarbonate reabsorption inhibitors (WO 00/15185, Beck et al)., it is believed that the present invention may target sweat ducts producing particularly low pH sweat.
Thus, according to a first aspect of the present invention, there is provided a cosmetic method of reducing the acidity of sweat excreted from human eccrine glands, said method comprising the topical application of a V-ATPase inhibitor to the skin in the vicinity of the eccrine glands.
The higher sweat pH resulting from the use of a V-ATPase inhibitor can lead to enhanced performance of an antiperspirant salt also applied.
Thus, according to a second aspect of the present invention, there is provided a cosmetic method of reducing perspiration, said method comprising the topical application of an antiperspirant salt and a V-ATPase inhibitor to the human skin.
According to a third aspect of the present invention, there is provided a method of enhancing the efficacy of a topically-applied antiperspirant salt, said method comprising the co-application of a V-ATPase inhibitor to the human skin.
According to a fourth aspect of the present invention, there is provided a deodorant product comprising a V-ATPase inhibitor and an antiperspirant salt.
According to a fifth aspect of the present invention, there is provided a method of manufacture of a deodorant composition, said method comprising the mixing of an antiperspirant salt and a V-ATPase inhibitor with a carrier material.
The higher sweat pH resulting from the use of a V-ATPase inhibitor may also lead to enhanced appreciation of topically-applied perfume. This may arise as a result of the perfume smelling better at the higher pH attained; as a result of reduced body malodour resulting from decreased volatility of odiferous fatty acids on the skin surface; as a result of reduced acid-induced damage of said perfume; or as a result of any other mechanism.
Thus, according to a sixth aspect of the present invention, there is provided a cosmetic product comprising a V-ATPase inhibitor and a perfume.
According to a seventh aspect of the present invention, there is provided a method of manufacture of a cosmetic composition, said method comprising the mixing of a perfume and a V-ATPase inhibitor with a carrier material.
DETAILED DESCRIPTION OF THE INVENTION
The elevation of sweat pH brought about by the V-ATPase inhibitor can lead to numerous benefits, as mentioned hereinbefore. For the benefits requiring the co-application of a perfume or an antiperspirant salt, it is not essential that the perfume or antiperspirant salt be applied as part of the same composition as the V-ATPase inhibitor. The benefit may be derived from independent application of the antiperspirant salt or perfume and the V-ATPase inhibitor. Co-application may be concurrent or consecutive, although it is preferred that the V-ATPase inhibitor is applied before or at the same time as the perfume or antiperspirant salt.
In one particular embodiment of the invention, the V-ATPase inhibitor is applied first, such as from a night-time product, for example a cosmetic cream or spray, and a perfume or antiperspirant salt is applied after the luminal membrane proton pump has been inhibited, for example the following morning, from a deodorant composition. In a related embodiment of the invention, the V-ATPase inhibitor is applied from a personal cleansing composition and, after drying, a perfume or antiperspirant salt is applied from a deodorant composition. In a further related embodiment of the invention, the V-ATPase inhibitor and a perfume or antiperspirant salt are simultaneously applied from independent cosmetic compositions. In all products of these types, where the V-ATPase inhibitor and the perfume or antiperspirant salt are applied from independent cosmetic compositions, it is preferred that the product also comprises a means for, and/or instruction for, both of the compositions to be applied to the body.
In another embodiment of the invention, the V-ATPase inhibitor and a perfume or antiperspirant salt are present in the same composition.
Preferred compositions comprising the products of the invention are deodorant compositions, in particular deodorant antiperspirant compositions.
In products comprising a V-ATPase inhibitor and a perfume and/or antiperspirant salt, and in methods of their use, the product is of particular benefit when used on an often malodorous region of the human body, for example the underarm areas or the feet.
Other compositions comprising the products of the invention are skin-care compositions, in particular creams, lotions, and gels.
The V-ATPase Inhibitor
The V-ATPase inhibitor may be any of the materials known in the art to function in this manner. Examples include the V-ATPase inhibitors described in the references cited hereinbefore and incorporated herein by reference. In the present invention, the V-ATPase inhibitor serves to inhibit V-ATPase in the luminal cells of the eccrine sweat gland, particularly the cells of the reabsorptive duct. This leads to a reductio
Beck Jonathan Samuel
Burry Jason Shaun
Evans Richard Livesey
Granger Dominic
Laprade Raynald
Dodson Shelley A.
Stein Kevin J.
Unilever Home & Personal Care USA , division of Conopco, Inc.
LandOfFree
Cosmetic products for the reduction of sweat acidity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cosmetic products for the reduction of sweat acidity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cosmetic products for the reduction of sweat acidity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3019324